Oral Hedgehog-Pathway Inhibitors for Basal-Cell Carcinoma
Ces deux essais évaluent l'activité et la toxicité du vismodegib, un inhibiteur de la voie Hegdehog, pour le traitement d'un naevus basocellulaire ou d'un carcinome basocellulaire localement avancé
Basal-cell carcinoma of the skin is the most common cancer worldwide, and its prevalence is increasing, accounting for 80% of nonmelanoma skin cancers. In 2006, more than 2.1 million new cases of nonmelanoma skin cancer were treated in the United States. Basal-cell carcinoma has many clinical subtypes and can progress to an advanced state in which surgery or radiation therapy is not considered to be helpful (locally advanced basal-cell carcinoma). Such lesions arise either from earlier lesions that have not been treated or from a recurrence of aggressive basal-cell carcinoma. Metastatic basal-cell carcinoma is rare.
New England Journal of Medicine , éditorial, 2011